MedTrace Logo

Faster Aspart on Insulin-pump Treated T1DM Patients

NCT04233203 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2021-02-01

No results posted yet for this study

Summary

Observational retrospective study about effectiveness and safety of insulin Faster Aspart on continuous subcutaneous insulin infusion treated adult Type 1 Diabetes Mellitus (T1DM) patients in routine clinical practice.

Conditions

Interventions

DRUG

Insulin Faster Aspart

Currently receiving Faster Aspart during 3 or more months.

DEVICE

Insulin pump

Currently receiving CSII therapy during 6 or more months.

Sponsors & Collaborators

  • University of Castilla-La Mancha

    collaborator OTHER

  • Jesús Moreno Fernández

    lead OTHER

Principal Investigators

  • Jose Alberto Garcia Seco, RN · Ciudad Real General University Hospital

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04233203 on ClinicalTrials.gov